Cargando…

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamad, Ahmad, Sahli, Zeyad, El Sabban, Maya, Mouteirik, Maha, Nasr, Rihab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725740/
https://www.ncbi.nlm.nih.gov/pubmed/23935640
http://dx.doi.org/10.1155/2013/724360
_version_ 1782278580372242432
author Hamad, Ahmad
Sahli, Zeyad
El Sabban, Maya
Mouteirik, Maha
Nasr, Rihab
author_facet Hamad, Ahmad
Sahli, Zeyad
El Sabban, Maya
Mouteirik, Maha
Nasr, Rihab
author_sort Hamad, Ahmad
collection PubMed
description Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML.
format Online
Article
Text
id pubmed-3725740
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37257402013-08-09 Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells Hamad, Ahmad Sahli, Zeyad El Sabban, Maya Mouteirik, Maha Nasr, Rihab Stem Cells Int Review Article Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML. Hindawi Publishing Corporation 2013 2013-07-09 /pmc/articles/PMC3725740/ /pubmed/23935640 http://dx.doi.org/10.1155/2013/724360 Text en Copyright © 2013 Ahmad Hamad et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hamad, Ahmad
Sahli, Zeyad
El Sabban, Maya
Mouteirik, Maha
Nasr, Rihab
Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title_full Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title_fullStr Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title_full_unstemmed Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title_short Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
title_sort emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725740/
https://www.ncbi.nlm.nih.gov/pubmed/23935640
http://dx.doi.org/10.1155/2013/724360
work_keys_str_mv AT hamadahmad emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells
AT sahlizeyad emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells
AT elsabbanmaya emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells
AT mouteirikmaha emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells
AT nasrrihab emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells